Esther Cho - 18 Aug 2026 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Reporting relationship: Chief Legal Officer
Issuer ticker: KROS
Reported as of: 18 Aug 2026
Net transaction value: -$46,151
SEC form: 4
Accepted by SEC: 20 Aug 2026, 16:10:08 UTC
Prior SEC filing: 27 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Esther Cho

Key filing fact

Esther Cho filed Form 4 for Keros Therapeutics, Inc. (KROS) on 20 Aug 2026.

Key facts

This page summarizes Esther Cho's Form 4 filing for Keros Therapeutics, Inc. (KROS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 20 Aug 2026, 16:10.

Change

Previous filing in this sequence was filed on 27 Mar 2026.
Current net transaction value: -$46,151.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002081460 Primary reporting owner

Cho Esther

Relationship: Chief Legal Officer
Address: C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON
Signature: /s/ Esther Cho
Signature date: 20 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KROS transaction

Common Stock

Sale

Transaction value: $46,151
Shares: -4,485
Change %: -11%
Price: $10.29
Shares after: 35,770
Date: 18 Aug 2026
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.14 to $10.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

Includes an aggregate of 500 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan.